Page last updated: 2024-08-21

methylnitrosourea and sulindac

methylnitrosourea has been researched along with sulindac in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (50.00)	18.2507
2000's	1 (50.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Ahnen, DJ; Jiang, C; Lu, J; Mehta, RG; Pamukcu, R; Paranka, NS; Piazza, GA; Thompson, HJ	1
Bosland, MC; Horton, L; Narayanan, BA; Narayanan, NK; Nargi, D; Randolph, C; Reddy, BS	1

Other Studies

2 other study(ies) available for methylnitrosourea and sulindac

Article	Year
Sulfone metabolite of sulindac inhibits mammary carcinogenesis. Cancer research, 1997, Jan-15, Volume: 57, Issue:2 Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Antineoplastic Agents; Carcinogens; Drug Screening Assays, Antitumor; Female; Genes, ras; Mammary Neoplasms, Experimental; Methylnitrosourea; Organ Culture Techniques; Rats; Rats, Sprague-Dawley; Sulindac	1997
Exisulind in combination with celecoxib modulates epidermal growth factor receptor, cyclooxygenase-2, and cyclin D1 against prostate carcinogenesis: in vivo evidence. Clinical cancer research : an official journal of the American Association for Cancer Research, 2007, Oct-01, Volume: 13, Issue:19 Topics: Animals; Anticarcinogenic Agents; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Cyclin D1; Cyclooxygenase 2; Cyclooxygenase Inhibitors; ErbB Receptors; Humans; Male; Methylnitrosourea; Prostatic Neoplasms; Pyrazoles; Rats; Rats, Wistar; Receptors, Androgen; Sulfonamides; Sulindac; Testosterone	2007

Article

Year

Sulfone metabolite of sulindac inhibits mammary carcinogenesis.

Cancer research, 1997, Jan-15, Volume: 57, Issue:2

Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Antineoplastic Agents; Carcinogens; Drug Screening Assays, Antitumor; Female; Genes, ras; Mammary Neoplasms, Experimental; Methylnitrosourea; Organ Culture Techniques; Rats; Rats, Sprague-Dawley; Sulindac

1997

Exisulind in combination with celecoxib modulates epidermal growth factor receptor, cyclooxygenase-2, and cyclin D1 against prostate carcinogenesis: in vivo evidence.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2007, Oct-01, Volume: 13, Issue:19

Topics: Animals; Anticarcinogenic Agents; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Cyclin D1; Cyclooxygenase 2; Cyclooxygenase Inhibitors; ErbB Receptors; Humans; Male; Methylnitrosourea; Prostatic Neoplasms; Pyrazoles; Rats; Rats, Wistar; Receptors, Androgen; Sulfonamides; Sulindac; Testosterone

2007